BridgeBio Pharma Gross Profit 2018-2025 | BBIO
BridgeBio Pharma annual/quarterly gross profit history and growth rate from 2018 to 2025. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- BridgeBio Pharma gross profit for the quarter ending March 31, 2025 was $0.114B, a 45.85% decline year-over-year.
- BridgeBio Pharma gross profit for the twelve months ending March 31, 2025 was $0.121B, a 43.8% decline year-over-year.
- BridgeBio Pharma annual gross profit for 2024 was $0.218B, a 3079.58% increase from 2023.
- BridgeBio Pharma annual gross profit for 2023 was $0.007B, a 90.76% decline from 2022.
- BridgeBio Pharma annual gross profit for 2022 was $0.074B, a 11.43% increase from 2021.
BridgeBio Pharma Annual Gross Profit
(Millions of US $) |
| 2024 |
$218 |
| 2023 |
$7 |
| 2022 |
$74 |
| 2021 |
$67 |
| 2020 |
$8 |
| 2019 |
$38 |
| 2018 |
$0 |
| 2017 |
$0 |
BridgeBio Pharma Quarterly Gross Profit
(Millions of US $) |
| 2025-03-31 |
$114 |
| 2024-12-31 |
$4 |
| 2024-09-30 |
$2 |
| 2024-06-30 |
$2 |
| 2024-03-31 |
$211 |
| 2023-12-31 |
$1 |
| 2023-09-30 |
$3 |
| 2023-06-30 |
$1 |
| 2023-03-31 |
$1 |
| 2022-12-31 |
$1 |
| 2022-09-30 |
$0 |
| 2022-06-30 |
$73 |
| 2022-03-31 |
$0 |
| 2021-12-31 |
$11 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$54 |
| 2021-03-31 |
$0 |
| 2020-12-31 |
$0 |
| 2020-09-30 |
$8 |
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
$14 |
| 2019-09-30 |
$24 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$7.257B |
$0.222B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
